-
- Company
Acquisition will advance Merck’s integrated offering for viral vector manufacturing.
Merck Signs Definitive Agreement to Acquire Life Science Company Mirus Bio for US$ 600 million
– Acquisition will advance Merck’s integrated offering for viral vector manufacturing
– Complements existing portfolio for development and production of novel modalities such as cell and gene therapies
– Novel modalities are a key growth area for Merck’s Life Science business sector
Merck, a leading science…